Anika Therapeutics (ANIK) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to -$80.2 million.
- Anika Therapeutics' Enterprise Value rose 1162.63% to -$80.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$80.2 million, marking a year-over-year increase of 1162.63%. This contributed to the annual value of -$79.2 million for FY2024, which is 1669.51% up from last year.
- According to the latest figures from Q3 2025, Anika Therapeutics' Enterprise Value is -$80.2 million, which was up 1162.63% from -$77.1 million recorded in Q2 2025.
- Over the past 5 years, Anika Therapeutics' Enterprise Value peaked at -$75.4 million during Q1 2025, and registered a low of -$124.2 million during Q4 2021.
- Over the past 5 years, Anika Therapeutics' median Enterprise Value value was -$97.2 million (recorded in 2021), while the average stood at -$100.3 million.
- In the last 5 years, Anika Therapeutics' Enterprise Value skyrocketed by 3268.62% in 2021 and then crashed by 3404.08% in 2022.
- Quarter analysis of 5 years shows Anika Therapeutics' Enterprise Value stood at -$124.2 million in 2021, then grew by 2.64% to -$121.0 million in 2022, then rose by 21.38% to -$95.1 million in 2023, then rose by 16.7% to -$79.2 million in 2024, then decreased by 1.2% to -$80.2 million in 2025.
- Its last three reported values are -$80.2 million in Q3 2025, -$77.1 million for Q2 2025, and -$75.4 million during Q1 2025.